Letter of Intent Signed with Lotus Energy Recycling for Canadian Joint VentureTo Collaborate on Recycling End-of-Life Photovoltaic (PV) Cells and Solar Panels in North America Focus on Recovering Valuable Silicon Materials for Battery Applications Initiated Recovered Silicon Material Testing and Evaluation for Anode Active Material Development in Lithium-Ion Batteries TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “Company”) (TSXV: NBM) (OTC: NBMFF), a low-cost silicon a ...

A downtrend has been apparent in NeoGenomics (NEO) lately. While the stock has lost 6.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support. The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the s ...

Joint Development Agreement with Fortune Global 500 Chemical Materials Company Multi-Billion Annual Revenue Generation with 40,000+ Employees in Over 50 Countries Developing Silicon Anode Products with Advanced Coating Materials and Methods To Enhance Structural Durability and Limit Battery Capacity Degradation Intention to Commercialize Jointly Developed Silicon Anodes Based on Performance TORONTO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. ("NEO" or the "Company") (TSXV: NBM) (OTC: NBMFF ...

Shares of NeoGenomics Inc (NEO, Financial) surged 3.95% in mid-day trading on Oct 2. The stock reached an intraday high of $14.36, before settling at $14.36, up from its previous close of $13.81. This places NEO 32.35% below its 52-week high of $21.22 and 30.15% above its 52-week low of $11.03. Trading volume was 213,519 shares, 33.0% of the average daily volume of 647,142. Wall Street Analysts Forecast Based on the one-year price targets offered by 12 analysts, the average target price for NeoGenomics Inc ...

Core Summary - AerCap has signed lease agreements with Azerbaijan Airlines (AZAL) for six new Airbus CFM LEAP-powered aircraft, including three A320neos and three A321neos, with deliveries scheduled for 2026 [1] - The A320neo and A321neo are highly desirable and fuel-efficient aircraft, enabling AZAL to expand its fleet, serve more customers, and modernize its operations [2] - AZAL aims to enhance passenger comfort, expand its route network, and improve service quality through this fleet expansion, while also strengthening its credibility in the international aviation market [2] - AerCap is a global leader in aviation leasing, serving approximately 300 customers worldwide with a strong order book and a presence in key global locations [3] AerCap's Role and Industry Position - AerCap is the global leader in aviation leasing, with one of the most attractive order books in the industry [3] - The company serves approximately 300 customers worldwide, offering comprehensive fleet solutions [3] - AerCap is listed on the New York Stock Exchange (AER) and has a global presence with offices in Dublin, Shannon, Miami, Singapore, Memphis, Amsterdam, Shanghai, Dubai, Seattle, Toulouse, and other locations [3] AZAL's Fleet Expansion and Strategic Goals - AZAL has signed lease agreements for six new Airbus aircraft, including three A320neos and three A321neos, to support its fleet modernization and network expansion [1][2] - The A320neo and A321neo are among the most in-demand aircraft globally, offering advanced fuel efficiency and technological features [2] - AZAL aims to improve passenger comfort, expand its route network, and enhance service quality, aligning with its commitment to meeting evolving customer expectations [2] - The partnership with AerCap underscores AZAL's credibility in the international aviation market [2]

TORONTO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (TSXV: NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, has closed the Share Purchase Agreement (the "Transaction") of NBM Korea Co., Ltd., ("NBM Korea") with Automobile & PCB Inc. ("A&P") pursuant to TSX Venture Exchange (the "Exchange") Policy 5.3 – Acquisitions and Dispositions of Non-Cash Assets ("Policy 5.3") but is contingent on fulfilling certain con ...

TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTC: NBMFF) Silicon Anode Technology Advancement with Extended Capacity Performance & Sustained Low-Cost Advantage Record-High Battery Performance Metric that Meets or Exceeds Industry Standards and Similar Commercial Products Two-Way Coating Enhancement: Simple, Feasible, and Low-Cost Planned Release of New Silicon-Carbon (Si-C) Anode Product Due to High Working Party & Industry Demand Recycled Silicon Evaluation In-Progress with Lotus Energy & INNOX ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 NEOGENOMICS, INC. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements ...

anodes to screen for compatibility. These tests will be the key to moving to the following stages with battery cell and EV manufacturers. This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Generally, such forward-looking information can be identified notably, but not limited to, by the use of forward-looking t ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 12% year-over-year, reaching $165 million, driven by clinical test volume growth and improvements in revenue per test [53][64] - Adjusted gross profit increased by 20% to $78 million, with adjusted gross margins improving by 320 basis points to 47.3% [53][96] - Adjusted EBITDA improved significantly by 630% from the prior year to positive $11 million, marking the fourth consecutive quarter of positive adjusted EBITDA [53][56] Business Line Data and Key Metrics Changes - Clinical Services revenue was $141 million, a 15% increase over the prior year, driven by a 9% increase in revenue per test and a 6% increase in volume [95] - The NGS (Next Generation Sequencing) segment grew approximately 40%, representing 30% of total clinical revenue [41][53] - Revenue from the combined pharma and informatics segment declined 3% year-over-year to $23.1 million, but increased sequentially by 6.5% over Q1 [55] Market Data and Key Metrics Changes - The company is seeing strong demand for NGS testing, particularly in the community oncology setting, which is driving higher volume growth [95][138] - The company is expanding its commercial coverage and reducing denials through RCM initiatives, which is expected to enhance revenue growth [42][95] Company Strategy and Development Direction - The company is focused on integrating with customers through EMR systems to enhance patient care and streamline data transfer [2][3] - Plans to launch new products, including a rapid AML test and a liquid biopsy CTP test, are set for the second half of the year, which are expected to strengthen the company's market position [41][45][71] - The company aims to leverage its informatics business by utilizing oncology diagnostic data from over 0.5 million patients annually [48][73] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain performance and achieve double-digit growth, supported by new product launches and sales force optimization [64][99] - The company is optimistic about the future, raising its adjusted EBITDA guidance significantly due to strong performance in the first half of the year [56][80] Other Important Information - The company is committed to developing new MRD (Minimal Residual Disease) assays and exploring strategic partnerships to enhance its offerings [75][146] - The company ended the second quarter with cash and marketable securities of $388 million, indicating a strong liquidity position [97] Q&A Session Summary Question: What is the mix of the NGS business between solid tumor and heme? - Management indicated that while they do not break out the specifics, heme has enabled a better presence in solid tumors due to market leadership [83][102] Question: Can the rapid turnaround time of AMLExpress be applied to other tests? - Currently, the rapid turnaround time is specific to AML, but there are opportunities for similar formats in other indications in the future [94][133] Question: What are the main drivers for the increased revenue guidance? - The increase is attributed to strong performance in the first half, new product launches, and successful sales force expansion [130][135]